Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Gilead’s Combination Hep C Drug Likely to Win Japan Approval Late June
May 29, 2015
- Pay Heed to Company Burdens for Cost-Effective Evaluations, Kamoya Tells Chuikyo
May 28, 2015
- MHLW Eyes Budget Request to Set Up Cost-Effective Analysis Regime, Report Due Out Summer
May 28, 2015
- MHLW Approves MSD’s Pegintron for Adjuvant Therapy for Malignant Melanoma
May 27, 2015
- MHLW to Set Generic Share Target of 80% by FY2020-End: Shiozaki
May 27, 2015
- MHLW Notifies of Package Insert Change for Plavix
May 27, 2015
- ICH Likely to OK Brazil, China as Assembly Members at Fukuoka Confab
May 26, 2015
- MHLW Grants Orphan Designation for Rituximab, Metirosine
May 26, 2015
- PAFSC 1st Committee to Review Lilly’s GLP-1 Receptor Agonist Dulaglutide on June 5
May 25, 2015
- Editor’s Pick: Five Healthcare News Headlines for May 11 - May 24
May 25, 2015
- Considerable Resolve Needed for Proposed 80% Generic Target: JGA
May 25, 2015
- JSGM President Muto Calls for “Favorable Environment” to Promote Use of Biosimilars
May 25, 2015
- Govt Panel Members Renew Call for Annual Drug Price Cuts, Amari Says Conclusion Out after 2016-2018 Consecutive Revisions
May 20, 2015
- Panel OKs Sovaldi for Medical Subsidy, Monthly Copay at 10,000-20,000 Yen
May 19, 2015
- Generic Drug Use May Reach 60% Target Ahead of Schedule, but Raising Target to 80% Would Be “Difficult”: Director Jo of EAD
May 18, 2015
- PAFSC Second Committee to Review Safety Information of Takeda’s Hib Vaccine on May 28
May 18, 2015
- MHLW Announces 196 Newly Designated Intractable Diseases
May 15, 2015
- PAFSC Second Committee to Discuss Gilead’s Combination Hepatitis C Treatment on May 28
May 15, 2015
- Chuikyo Reps Discuss HTA, Re-Pricing as Sovaldi Lands in Japan
May 14, 2015
- Chuikyo Approves Listing of 5 Drugs with Expected Peak Sales of Over 10 Billion Yen
May 14, 2015
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…